Osteogenesis imperfecta is a heritable disease of connective tissue that results from a wide variety of mutations of type I collagen. This grant outlines a series of protocols designed to define these abnormalities at the molecular level. It is based on the assumption that it is easier to define the mutations in collagen by studying the mRNA rather than its very complex gene. Fibroblasts derived from patients with 0I will be used as a source of RNA. Structural mutation of the alpha 1 or alpha 2 collegen mRNA will be localized using a series of end-labeled S1 probes that encompass the entire mRNA. The probes will be derived from single-stranded cDNAs cloned in M-13. The exact mutation will be defined by dideoxy sequencing of an extended cDNA initiated from a synthetic oligonucleotide primer complementary to a region 3' to the region suggested of having the abnormality as dictated by the S-1 protection experiments. Another oligo-nucleotide coding for the abnormal sequence will be constructed and used as a mutation specific hybridization probe to precisely localize the mutation to the gene. Mutations which alter the steady state level of collagen mRNA will be tested for an error of RNA processing using a novel application of the M-13 derived hybridization probe. This will involve an S-1 protection protocol to detect an accumulation of a specific unspliced mRNA, measurement of half-life of a normal and mutant cytoplasmic mRNA and solution hybridization of radiolabeled RNA from in vitro transcribed muclei. The methods that are developed in this grant will have general applicability to a wide variety of mutations involving type I collagen. The mutation-specific oligonucleotides provide the means to rapidly detect a subtle mutation in genomic DNA. It has the potential to become a very powerful adjuvant for the clinical geneticist who must counsel a family with a connective tissue disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR030426-13
Application #
2078686
Study Section
General Medicine B Study Section (GMB)
Project Start
1982-04-01
Project End
1996-03-31
Budget Start
1994-09-30
Budget End
1996-03-31
Support Year
13
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Connecticut
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
Farmington
State
CT
Country
United States
Zip Code
06030
Liu, Peng; Kronenberg, Mark; Jiang, Xi et al. (2004) Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript. Nucleic Acids Res 32:1512-7
Fortes, Puri; Cuevas, Yolanda; Guan, Fei et al. (2003) Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A 100:8264-9
Liu, Peng; Gucwa, Amy; Stover, Mary Louise et al. (2002) Analysis of inhibitory action of modified U1 snRNAs on target gene expression: discrimination of two RNA targets differing by a 1 bp mismatch. Nucleic Acids Res 30:2329-39
Beckley, S A; Liu, P; Stover, M L et al. (2001) Reduction of target gene expression by a modified U1 snRNA. Mol Cell Biol 21:2815-25
Johnson, C; Primorac, D; McKinstry, M et al. (2000) Tracking COL1A1 RNA in osteogenesis imperfecta. splice-defective transcripts initiate transport from the gene but are retained within the SC35 domain. J Cell Biol 150:417-32
Redford-Badwal, D A; Stover, M L; Valli, M et al. (1996) Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. J Clin Invest 97:1035-40
Stover, M L; Primorac, D; Liu, S C et al. (1993) Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta. J Clin Invest 92:1994-2002
Shapiro, J R; Stover, M L; Burn, V E et al. (1992) An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen. J Clin Invest 89:567-73